Views & Analysis | Perspectives on pharma industry issues

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

Articles

mHealth Monthly Mashup: release 2.0 - peering into the fut...

Checking in to his next instalment in the series, Michael Spitz discusses the issuance of draft guidelines for mobile health applications from the FDA, and what they might mean for physicians, patients and caregivers, and the mHealth industry. Although the issuance of draft guidance for mobile medical applications by the FDA on July 19th came ...

Articles

Ethical reflections: to achieve true transparency, doctors n...

In her new series addressing pharma ethics, Claire Nicholson broaches the subject of the physician. Should they be demonstrating increased accountability and openness if we are to achieve true transparency? In recent years the pharmaceutical industry has been making a concerted effort to try and address its public image issue and become...

Articles

Patient reminder programs - increasing compliance and reduci...

Bernie Thomas gives an overview of the benefits of patient reminder programs and what an ideal program will entail. Patients don’t mean to forget, they are busy, stressed, in pain or suffering. Your clinical trial protocol and study end points are probably...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.